{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T22:02:30Z","timestamp":1781215350859,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"DOI":"10.7759\/cureus.110686","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:54:36Z","timestamp":1781214876000},"source":"Crossref","is-referenced-by-count":0,"title":["Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid in an Elderly Woman With Type 2 Diabetes Mellitus: A Case Report"],"prefix":"10.7759","author":[{"given":"Guillermo","family":"Roa Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Shuchleib Cukiert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix R","family":"Hern\u00e1ndez Altamirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Berumen Glinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E","family":"Vega Memije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell DF","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P, et al.. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012, 66:479-485. 10.1016\/j.jaad.2011.06.032","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16A protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi M","year":"2002","unstructured":"Kobayashi M, Amagai M, Kuroda-Kinoshita K, Hashimoto T, Shirakata Y, Hashimoto K. BP180 ELISA using bacterial recombinant NC16A protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci. 2002, 30:224-232. 10.1016\/S0923-1811(02)00109-3","journal-title":"J Dermatol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","volume":"161","author":"Marazza G","year":"2009","unstructured":"Marazza G, Pham HC, Sch\u00e4rer L, et al.. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009, 161:861-868. 10.1111\/j.1365-2133.2009.09300.x","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database","volume":"175","author":"B\u00e9n\u00e9 J","year":"2016","unstructured":"B\u00e9n\u00e9 J, Moulis G, Bennani I, et al.. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol. 2016, 175:296-301. 10.1111\/bjd.14601","journal-title":"Br J Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland","volume":"78","author":"Benzaquen M","year":"2018","unstructured":"Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, Feldmeyer L. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018, 78:1090-1096. 10.1016\/j.jaad.2017.12.038","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study","volume":"138","author":"Varpuluoma O","year":"2018","unstructured":"Varpuluoma O, F\u00f6rsti AK, Jokelainen J, Turpeinen M, Timonen M, Huilaja L, Tasanen K. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J Invest Dermatol. 2018, 138:1659-1661. 10.1016\/j.jid.2018.01.027","journal-title":"J Invest Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients","volume":"154","author":"Kridin K","year":"2018","unstructured":"Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol. 2018, 154:1152-1158. 10.1001\/jamadermatol.2018.2352","journal-title":"JAMA Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes","volume":"155","author":"Lee SG","year":"2019","unstructured":"Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019, 155:172-177. 10.1001\/jamadermatol.2018.4556","journal-title":"JAMA Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3010","article-title":"Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: recurrence with epitope spreading","volume":"98","author":"Takama H","year":"2018","unstructured":"Takama H, Yoshida M, Izumi K, et al.. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: recurrence with epitope spreading. Acta Derm Venereol. 2018, 98:983-984. 10.2340\/00015555-3010","journal-title":"Acta Derm Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3166","article-title":"Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4\/CD26 in bullous pemphigoid","volume":"99","author":"Lindgren O","year":"2019","unstructured":"Lindgren O, Varpuluoma O, Tuusa J, Ilonen J, Huilaja L, Kokkonen N, Tasanen K. Gliptin-associated bullous pemphigoid and the expression of dipeptidyl peptidase-4\/CD26 in bullous pemphigoid. Acta Derm Venereol. 2019, 99:602-609. 10.2340\/00015555-3166","journal-title":"Acta Derm Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi K","year":"2016","unstructured":"Izumi K, Nishie W, Mai Y, et al.. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol. 2016, 136:2201-2210. 10.1016\/j.jid.2016.06.622","journal-title":"J Invest Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16479","article-title":"Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors","volume":"178","author":"Horikawa H","year":"2018","unstructured":"Horikawa H, Kurihara Y, Funakoshi T, et al.. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol. 2018, 178:1462-1463. 10.1111\/bjd.16479","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.023","article-title":"HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors","volume":"138","author":"Ujiie H","year":"2018","unstructured":"Ujiie H, Muramatsu K, Mushiroda T, et al.. HLA-DQB1*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol. 2018, 138:1201-1204. 10.1016\/j.jid.2017.11.023","journal-title":"J Invest Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani C","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, et al.. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015, 172:867-877. 10.1111\/bjd.13717","journal-title":"Br J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/504056-dipeptidyl-peptidase-4-inhibitor-associated-bullous-pemphigoid-in-an-elderly-woman-with-type-2-diabetes-mellitus-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:54:37Z","timestamp":1781214877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/504056-dipeptidyl-peptidase-4-inhibitor-associated-bullous-pemphigoid-in-an-elderly-woman-with-type-2-diabetes-mellitus-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.110686","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}